N-(Methylcarbamoyl)acetamido N-methylcarbamate
CAS: 81424-67-1
Ref. 3D-GDA42467
25mg | 359,00 € | ||
250mg | 1.435,00 € |
Produktinformation
- (Acetyl-(methylcarbamoyl)amino) N-methylcarbamate
- Acetamide, N-((methylamino)carbonyl)-N-((methylamino)carbonyl)oxy)-
- Brn 5935912
- Caracemida
- Caracemida [Spanish]
- Caracemide [USAN:INN]
- Caracemidum
- Caracemidum [Latin]
- Ccris 1729
- N-((Methylamino)carbonyl)-N-(((methylamino)carbonyl)oxy)acetamide
- Mehr Synonyme anzeigen
- N-(Methylcarbamoyl)-N-(methylcarbamoyloxy)acetamid
- N-(methylcarbamoyl)-N-[(methylcarbamoyl)oxy]acetamide
- N-Acetyl-N,O-bis(methylcarbamoyl)hydroxylamine
- N-Acetyl-N,O-di(methylcarbamoyl)hydroxylamine
- N-Acetyl-N-(methylcarbamoyloxy)-N'-methylurea
- Nsc 253272
- Unii-H74F6J185A
- Caracemide
N-(Methylcarbamoyl)acetamido N-methylcarbamate (NMCA) is a novel anti-cancer compound that selectively binds to the CB2 receptor. NMCA has been shown to inhibit the growth of cancer cells in vitro and in vivo, as well as reduce the size of bowel tumors. It also has a beneficial effect on cardiac function. The mechanism of action is not completely understood, but it may be due to binding to the CB2 receptor and blocking the activation of other receptors such as TNF-α. NMCA can be formulated into biocompatible polymers that are suitable for drug delivery. Furthermore, this compound can be used for treating inflammatory bowel disease and renal cell cancer.
Chemische Eigenschaften
Technische Anfrage zu: 3D-GDA42467 N-(Methylcarbamoyl)acetamido N-methylcarbamate
Wenn Sie ein Angebot anfordern oder eine Bestellung aufgeben möchten, legen Sie stattdessen die gewünschten Produkte in Ihren Warenkorb und fordern Sie dann ein Angebot oder eine Bestellung an aus dem Warenkorb. Es ist schneller, billiger und Sie können von den verfügbaren Rabatten und anderen Vorteilen profitieren.